The overexpression of DEK is found in a majority of solid tumors, including retinoblastoma (Grasemann et al., 2005), adenocarcinoma (Piao et al., 2014), lung cancer (Shibata et al., 2010; Wang et al., 2014; Yang et al., 2020), bladder cancer (Carro et al., 2006; Datta et al., 2011), prostate cancer (Lin et al., 2015), cervical cancer (Wu et al., 2008), melanoma (Khodadoust et al., 2009), breast cancer (Liu et al., 2012; Privette Vinnedge et al., 2015), and esophageal (Yi et al., 2015) and oral squamous cell carcinoma (Nakashima et al., 2017). Here, DEK is linked to breast carcinoma.